{"id":698,"date":"2016-06-16T04:55:00","date_gmt":"2016-06-15T23:55:00","guid":{"rendered":"http:\/\/www.policymed.com\/detecting-the-sham-in-speaker-programs\/"},"modified":"2018-05-05T01:09:21","modified_gmt":"2018-05-04T20:09:21","slug":"detecting-the-sham-in-speaker-programs","status":"publish","type":"post","link":"https:\/\/www.policymed.com\/2016\/06\/detecting-the-sham-in-speaker-programs.html","title":{"rendered":"Detecting the \u201cSham\u201d in Speaker Programs"},"content":{"rendered":"<p style=\"text-align: justify;\">\n<p style=\"text-align: justify;\"><span style=\"color: #221e1f; font-family: Arial; font-size: 12pt;\">In late March 2016, Novartis Pharmaceuticals Corp. (NPC) and the U.S. Department of Justice and the State of New York (collectively, “Government”) corresponded with the presiding U.S. District Judge about an alleged “nationwide kickback scheme, spanning 10 years, to induce doctors to write prescriptions.” <\/span><\/p>\n<p><span style=\"color: #221e1f; font-family: Arial; font-size: 12pt;\">It is alleged by the Government that NPC routinely conducted “promotional events that had little to no educational value,” “frequently providing lavish meals,” allowing the “same doctors attend the same events over and over again” and other related allegations. From these correspondences, the Government has delineated nine factual bases for determining whether a speaker program is a “sham” and a potential violation of the Anti-Kickback Statue (AKS) and False Claims Act (FCA). <\/span><\/p>\n<p><span style=\"color: #221e1f; font-family: Arial;\"><span style=\"font-size: 12pt;\">We thought it would be significant if the\u00a0<\/span><span style=\"font-size: 16px;\">publicly<\/span><span style=\"font-size: 12pt;\">\u00a0available Open Payments data can be employed, <\/span><\/span><span style=\"color: #b9b9b9; background-color: #ffffff;\">using the same factual basis as the Government has stated, to detect potential “sham” speaker programs. <\/span><\/p>\n<p><a href=\"http:\/\/www.lifescicompliance.com\/june-2016-life-science-compliance-update-2\/\"><span style=\"font-family: Arial; font-size: 12pt;\">Read Full Article in the June 2016 Issue of Life Science Compliance Update<\/span><\/a><\/p>\n<div style=\"height: 30px; background: #336699; width: 750px; padding: 10px 0px 4px 20px; font-family: Verdana,sans-serif; font-size: 1.2em; color: white;\">To Read the Full Story, <a style=\"color: white;\" href=\"http:\/\/www.lifescicompliance.com\/subscription-options\/\"><strong>Subscribe<\/strong><\/a>, <strong>Download a <a style=\"color: white;\" href=\"https:\/\/www.lifescicompliance.com\/sample-issue-contact-information\/\">Sample Issue<\/a><\/strong>, or <a style=\"color: white;\" href=\"https:\/\/www.lifescicompliance.com\/login\/\"><strong>Sign In<\/strong><\/a><\/div>\n<div style=\"width: 770px;\"><a href=\"http:\/\/www.lifescicompliance.com\"><img decoding=\"async\" class=\"asset asset-image at-xid-6a00e5520572bb883401b8d1c8ad6d970c image-full img-responsive\" style=\"width: 770px;\" title=\"PM_LSCU_Box\" src=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b8d1c8ad6d970c-800wi\" alt=\"PM_LSCU_Box\" height=\"253\" border=\"0\" \/><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In late March 2016, Novartis Pharmaceuticals Corp. (NPC) and the U.S. Department of Justice and the State of New York (collectively, “Government”) corresponded with the presiding U.S. District Judge about an alleged “nationwide kickback scheme, spanning 10 years, to induce doctors to write prescriptions.” It is alleged by the Government that NPC routinely conducted “promotional […]<\/p>\n","protected":false},"author":1,"featured_media":4789,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40,55,41],"tags":[1101],"class_list":["post-698","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-anti-kickback","category-false-claims-act","category-life-science-compliance-update","tag-new"],"_links":{"self":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/comments?post=698"}],"version-history":[{"count":1,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/698\/revisions"}],"predecessor-version":[{"id":4790,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/698\/revisions\/4790"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media\/4789"}],"wp:attachment":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media?parent=698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/categories?post=698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/tags?post=698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}